2,160 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Edge Financial Advisors LLC

Edge Financial Advisors LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,160 shares of the medical equipment provider’s stock, valued at approximately $285,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. OLD Point Trust & Financial Services N A bought a new position in Zimmer Biomet in the fourth quarter valued at approximately $26,000. Ables Iannone Moore & Associates Inc. bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $30,000. Naples Money Management LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at approximately $35,000. Activest Wealth Management lifted its stake in Zimmer Biomet by 410.4% in the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 275 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in Zimmer Biomet by 48.4% during the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 153 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Barclays cut their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research report on Friday, May 31st. Truist Financial reduced their price objective on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research note on Friday, May 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, May 30th. Oppenheimer increased their price target on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Argus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research note on Tuesday, May 21st. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $131.76.

Zimmer Biomet Stock Performance

ZBH traded up $0.01 on Friday, reaching $106.59. The company had a trading volume of 133,931 shares, compared to its average volume of 1,495,074. The stock has a market cap of $21.93 billion, a P/E ratio of 23.07, a P/E/G ratio of 1.92 and a beta of 1.01. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $144.13. The company’s fifty day moving average is $114.14 and its 200 day moving average is $120.85.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating the consensus estimate of $1.87 by $0.07. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.89 earnings per share. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be given a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. Zimmer Biomet’s payout ratio is presently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.